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Abstract
Background: Idiopathic pulmonary arterial hypertension (IPAH) is a progressive and fatal cardiovascular disease if
left untreated. In patients with IPAH with psychiatric illness or other complications, careful attention is required
when administering medical therapies that may affect their hemodynamics. Patients suffering from IPAH who
undergo anesthesia and surgery have a high mortality and morbidity rate. We describe the treatment of intractable
psychiatric symptoms with electroconvulsive therapy (ECT) in a patient with IPAH.
Case presentation: A 23-year-old woman with IPAH and type I diabetes mellitus (DM) presented with malignant
catatonia. Her heart function was classified as New York Heart Association (NYHA) class III. She required a rapid cure
and ECT due to various psychiatric symptoms resistant to conventional medications. Pulmonary hypertensive (PH)
crisis is the most concerning complication that can be induced by the sympathetic stimulation of ECT. To avoid PH
crisis, we administered oxygen using a laryngeal mask and administered remifentanil for anesthesia. We also
prepared standby nitric oxide for possible PH crisis, although it was ultimately not needed. With 14 ECT sessions,
her malignant catatonia was ameliorated without physical complications.
Conclusion: ECT is an acceptable option for the treatment of medication-refractory psychiatric disturbances in
patients with IPAH, provided careful management is assured to prevent or address complications.
Keywords: Electroconvulsive therapy, Idiopathic pulmonary arterial hypertension, Malignant catatonia, Pulmonary
hypertensive crisis, Remifentanil
Background
Patients with idiopathic pulmonary arterial hypertension
(IPAH) who undergo anesthesia and surgery have a high
mortality and morbidity rate [1]. Careful attention is
required when administering medications or therapies
that may affect the patients’ hemodynamics. Regardless,
malignant catatonia is a life-threatening psychiatric condi-
tion that needs systemic care and a rapid cure. We treated
malignant catatonia in a patient with IPAH who eventually
required electroconvulsive therapy (ECT) that could have
affected her hemodynamics. This report describes the first
case of malignant catatonia with IPAH treated by ECT
and the risk-reducing procedures we used to prevent
physical complications.
Case presentation
A 23-year-old woman with a history of IPAH presented to
our service with malignant catatonia. She was diagnosed
with IPAH at the age of 8 due to her high mean pulmon-
ary arterial pressure (PAP) of 50 mmHg (a diagnosis of
IPAH is made if PAP is >25 mmHg according to the
World Symposium on Primary Pulmonary Hypertension
1998). Because her IPAH progressed despite treatment
with beraprost and home oxygen therapy, she began to
receive 24-hour infusions of epoprostenol (prostaglandin
I2) at the age of 12. Epoprostenol was temporarily effective
to improve pulmonary circulation, but when she was
23 years old, her heart function deteriorated to the New
* Correspondence: tnis.psyc@tmd.ac.jp
1Department of Psychiatry and Behavioral Sciences, Graduate School of
Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45
Yushima, Bunkyo-ku, Tokyo 113-8519, Japan
Full list of author information is available at the end of the article
© 2016 Hobo et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hobo et al. BMC Psychiatry  (2016) 16:130 
DOI 10.1186/s12888-016-0835-4
York Heart Association (NYHA) class III [2]. At age 16,
the patient was also diagnosed with insulin-resistant dia-
betes mellitus (DM) and was started on insulin injections.
The patient’s significant medical history also included
her psychiatric illnesses. She was hospitalized at the ages
of 20 and 21 because of attempted suicide under de-
pressed mood with psychomotor excitement and psych-
osis. Therefore, she had been treated with antidepressants
and antipsychotics for psychotic depression, but she was
later re-diagnosed with schizophrenia during the present
hospitalization.
At the age of 23 years, the patient became non-compliant
with psychiatric medications. One month later, she became
agitated and began muttering and then was gradually
rendered mute and cataleptic. Subsequently, she was hospi-
talized at our psychiatric ward because of a substuporous
state. Despite continuing her cardiovascular drugs, she was
physically unstable with tachycardia, hypertension, a fluctu-
ating blood glucose level ranging from 50 to 400 mg/dL,
and hyperthermia (up to 40.0 °C). The findings of cardiac
examination on admission are shown in Table 1. The medi-
cations used to treat these somatic problems were oral digi-
talis (0.125 mg/d), spironolactone (25 mg/d), warfarin
(2 mg/d), furosemide (40 mg/d), epoprostenol, and sub-
cutaneous insulin injections.
Head magnetic resonance imaging (MRI), electroen-
cephalography (EEG), and cerebrospinal fluid (CSF) ana-
lysis were unremarkable. We determined that the most
likely diagnosis for her condition, including delirium, mut-
ism, catalepsy, hyperpyrexia, posturing, and autonomic
instability, was malignant catatonia according to the cri-
teria of Fink [3]. The score on the Bush-Francis Catatonia
Rating Scale [4] was 23 on admission (Fig. 1). Lorazepam
(given orally, 3 mg per day) alleviated the substuporous
state, but she developed Capgras’ syndrome and persecu-
tory delusions and exhibited agitation. Levomepromazine
(50 mg/day) and aripiprazole (24 mg/day) were not effect-
ive for these symptoms. Because her autonomous and
hemodynamic instability was potentially life threatening,
we decided to introduce ECT using a square wave-
generating instrument (Thymatron System IV; Somatics,
LLC, Lake Bluff, IL, USA) after obtaining informed con-
sent from her family. To monitor for potential pulmonary
hypertensive (PH) crisis, which is the most serious compli-
cation of ECT, a pediatric cardiologist and medical engin-
eer carefully observed her cardiopulmonary status during
all ECT sessions. Endotracheal intubation was performed,
and standby nitric oxide (NO) inhalation was prepared in
case of PH crisis secondary to dilating pulmonary arteries.
Moreover, during each ECT procedure, epoprostenol was
continuously infused to prevent PH, and a combination of
propofol and remifentanil was used to induce anesthesia.
Remifentanil was chosen because it is a short acting opi-
oid with strong anti-nociceptive features and was expected
to stabilize blood pressure. Propofol was injected intraven-
ously using a target-controlled infusion (TCI) at blood
concentrations between 3 and 4 mcg/mL, which can keep
most patients unconscious, and remifentanil was infused
at 0.5-1.0 mg/h, followed by rocuronium (0.8 mg/kg) to
relax the muscles. TCI is a drug infusion technique that
combines a real-time pharmacokinetic model with an in-
fusion pump and allows the administration and mainten-
ance of a constant blood concentration of drug.
The ECT electrodes were positioned bilaterally through
all sessions. For the first ECT session, a stimulus dose of
25 % was administered, and seizures were observed for
59 s by electromyography (EMG) and 69 s by EEG.
Though the patient was expectedly tachycardic during the
intubation procedure and after convulsion, her blood
pressure was kept within the expected range. Therefore,
we speculated that pulmonary artery constriction did not
occur and that NO was not needed. Because she com-
plained of intense throat pain, we used a laryngeal mask
instead of intubation for subsequent ECT sessions. This
was determined after discussing with the anesthesiologists
who assured a laryngeal mask would be sufficient for NO
inhalation and oxygenation. Moreover, we speculated she
Table 1 Cardiac examination findings on admission
Current case Normal values
systolic 74 15–28
PAP (mmHg) diastolic 27 5–16
mean 45 10–22
CI (L/min/m2) 3.21 2.3–4.2
BNP (pg/ml) 133.4 <20
CR (%) 64 50
EF (%) 53 55–80
Oxygen Saturation (%) 90 96–99
PAP pulmonary arterial pressure, CI cardiac index, BNP brain natriuretic
peptide, CR cardiothoracic ratio, EF ejection fraction
Fig. 1 Time course of catatonia assessed by Bush- Francis Catatonia
Rating Scale Catatonia is rated at 23 on admission, and symptoms
are alleviated in response to ECT sessions. The down arrows indicate
each ECT session
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would need more than 10 ECT sessions but were con-
cerned she would not tolerate repeated intubation. As the
ECT sessions were repeated, the symptoms of malignant
catatonia, such as tachycardia, hypertension, fluctuating
blood glucose and hyperthermia, were gradually alleviated,
and these parameters were generally within the normal
ranges after the ninth session. Eventually, we completed
14 ECT sessions with an average stimulus dose of 56.6 %,
which is equivalent to 285 mC. The average seizure dura-
tions were 35.9 s on EMG and 39.3 s on EEG. The Bush-
Francis Catatonia Rating Scale score decreased to zero
after the last ECT session (Fig. 1). Upon completion of the
ECT, her mental state returned to her baseline. She was
discharged from the hospital 93 days after admission.
Follow-up was continued on an outpatient basis with the
patient in remission with the oral administration of aripi-
prazole (30 mg/day), valproic acid (600 mg/day), lorazepam
(1 mg/day), zotepine (150 mg/day), digitalis (0.125 mg/day),
spironolactone (25 mg/day), warfarin (2 mg/day), and
furosemide (40 mg/day) in addition to epoprostenol and
insulin therapies.
The patient and/or her family had shared their perspec-
tives on the treatments she received. In particular, when
the patient was considered to be not competent in terms
of understanding her medical condition, the treatment
team gave her family a full explanation regarding her con-
dition and treatment options, including ECT and medica-
tion treatments. Then, when the patient recovered well
enough to be competent, the same process was repeated
to obtain her informed consent.
Discussion
To our knowledge, this is the first report to describe ECT
application in a patient with IPAH. We administered ECT
and treated malignant catatonia complicated by IPAH.
ECT is considered to be a first-line treatment for malig-
nant catatonia [5, 6]. However, patients with IPAH who
undergo anesthesia and surgery have a high mortality and
morbidity rate. Indeed, it has recently been reported in a
series of patients with mild to moderate pulmonary hyper-
tension during non-cardiothoracic non-obstetric surgery
that 29 % of the patients had complications and that four
of 28 patients died [7].
In our patient, PH crisis was the most potential con-
cerning complication of ECT [8]. PH crisis is a conse-
quence of constricted pulmonary arteries, which is
induced by factors such as hypoxia or sympathetic stimu-
lation in patients with pulmonary hypertension. Rapidly
constricting pulmonary arteries in the PH crisis lead to
right heart failure and severe hypoxia [9]. These risks
can be effectively reduced based upon our clinical experi-
ences and based on published reports in the field of IPAH
and PH crisis [10]. First, we utilized endotracheal
intubation or a laryngeal mask in order to provide sufficient
oxygenation and to prevent hypercapnia. Second, we se-
lected remifentanil for anesthesia, because it has strong
anti-nociceptive features and was expected to stabilize
blood pressure [11]. Third, we had an NO appliance avail-
able in case of PH crisis.
Conclusion
ECT is an acceptable option for treatment of intractable
psychiatric symptoms in a patient with IPAH, provided
patients are managed carefully to prevent or address
potential complications.
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